Treatment of early gastric cancer in the Western World

Elfriede Bollschweiler, Felix Berlth, Christoph Baltin, Stefan Mönig, Arnulf H Hölscher

Department of General, Visceral and Cancer Surgery, University of Cologne, 50937 Cologne, Germany

Author contributions: Bollschweiler E, Mönig S and Hölscher AH are responsible for the scientific context of the manuscript; Berlth F and Baltin C performed the systematic search of literature; Bollschweiler E designed the review and wrote the manuscript.

Correspondence to: Elfriede Bollschweiler, Professor, Department of General, Visceral and Cancer Surgery, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. elfriede.bollschweiler@uk-koeln.de

Telephone: +49-221-4786273 Fax: +49-221-4785076

Received: October 29, 2013 Revised: January 3, 2014

Accepted: February 16, 2014 Published online: May 21, 2014

Abstract

The incidence rate of gastric cancer is much higher in Asia than in the Western industrial nations. According to the different screening programs in Japan and Korea about fifty percent of treated patients had an early tumor stage. In contrast, European and American patients with gastric cancer had an advanced tumor stage. Therefore, the experience for the various therapeutic options for gastric cancer may be different between these regions. In this review we tried to point out the treatment modalities in Western industrial countries for early gastric cancer.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Gastric cancer; Early cancer; Epidemiology; Diagnosis; Therapy; Western World

Core tip: Early gastric cancer is a challenging disease with varying lymph node infiltration. In the Western industrial countries the frequency of early gastric cancer is much lower than in Asian countries. Especially, carcinomas limited to the mucosa are rare in the West. Therefore the experience of endoscopic therapy or minimal invasive surgery is only in special centers available. Total or subtotal gastrectomy with D2-lymphadenectomy is the standard treatment for early gastric cancer with suspected lymph node metastases. Future studies including prediction of lymph node metastasis are necessary to optimize the therapy according to quality of life.

INTRODUCTION

Gastric cancer is the second most common cause of death from cancer worldwide[1]. Overall incidence rates for gastric cancer have steadily declined over the past 50 years, particularly in developed countries.

According to the Japanese classification of gastric cancer early gastric cancer (EGC) is defined as gastric cancer in which tumor invasion is confined to the mucosa or submucosa (T1 cancer), irrespective of the presence of lymph node metastasis[2]. Early gastric cancer carries a much more favourable prognosis than advanced cancer, with 5-year survival rates of over 90%[3]. A complete cure can almost always be achieved by conventional gastrectomy with lymph node dissection. Therefore, this treatment has been the gold standard, providing an excellent prognosis in patients with EGC in Eastern as well as in the Western world[3-5]. During the last years limited resection of the primary tumor and minimal invasive surgical approaches have been introduced for early gastric cancer[6]. On the other hand, endoscopic resection (ER) is beneficial, as it is minimally invasive and conserves the whole stomach, and postoperative quality of life is good[7,8].
ER has been accepted as a minimally invasive treatment method for EGC with a negligible risk of lymph node metastasis. But according to the low frequency of EGC in the Western countries the experience with minimal invasive surgical and endoscopic methods are low compared to those in Asian countries.

The aim of this review is to show the actual knowledge about early gastric cancer in Western industrial countries.

DEFINITION

The term “Early Gastric Cancer” is not really well defined. According to the Japanese classification of gastric cancer EGC is defined as gastric cancer in which tumor invasion is confined to the mucosa or submucosa (T1 cancer), irrespective of the presence of lymph node metastasis. Sometimes it is used to contrast it to “Advanced Gastric Cancer”. In these cases, EGC includes T2 cancers in addition to T1 cancer. According to the 7th UICC-TNM classification T1 means the tumour has started to grow into the wall of the stomach. T1 is further divided into T1a and T1b. T1a means the tumour is within the inner layers of the stomach (the mucosa). And T1b means the tumour has grown through the mucosa and into a layer of supportive tissue called the submucosa. The N-category describes the number of metastatic lymph nodes (LNM), N0 = no lymph node metastasis, N1 = 1-2 LNM, N2 = 3-6 LNM and N3 more than 6 LNM. The stage-system of the 7th UICC-TNM classification combined the T-, N-, and the M-category. Early gastric cancer is often used in the same manner as stage I tumor. In this stage system T1N0M0 (stage IA), T1N1M0 and T2N0M0 (stage IB) tumors are combined to stage I gastric cancer. T1N2M0 or T1N3M0 are classified to more advanced stages.

EGC AND LYMPH NODE METASTASES

Hölscher et al. compared the frequency of LNM in patients with pT1 gastric cancer from Asian and European countries. In European countries there were 6.5% for mucosal carcinomas and 23.9% for submucosal carcinomas compared to 2.7% resp. 22.9% in Asian countries. Table 1 shows the results of literature for patients with pT1 gastric cancer in the Western countries. One reason for the difference of LNM in pT1a cancer may be the higher frequency of tumor infiltration in the upper layer of the mucosa (m1 and m2) with no lymphatic invasion for Asian patients. The infiltration of the deepest layer (m3) represents an important step for a mucosal carcinoma. In the series from Hölscher et al. for German patients with mucosal carcinoma the rate of lymph node metastasis springs from 0% in m1 or m2 layers to 12.8% in m3 layer. Another reason for this dissimilarity may be different location of the primary tumor. Patients in Asian have more often tumor in the mid or lower third of the stomach compared to patients in Western countries with higher frequency of tumors in the proximal third. Further explanations, like biologic differences or differences in genomic or epigenomic changes, for differences in the frequency of LN metastasis between the two worlds are not really well studied and therefore topics of future studies.

EPIDEMIOLOGY

Nearly for all countries in the world the incidence rate of gastric cancer declined during the last fifty years. The main difference between Asian and Western industrial nations is the level of the incidence rate. Whereas in Japan an age standardized incidence rate (ASR) for males of about 80 per 100000 inhabitants were found in European countries the ASR for males is about 16 per 100000 inhabitants.

The frequencies of early gastric cancer in Western countries are not really known. According to the lower incidence rate of gastric cancer there exists no screening programs for this tumor entity. Faria et al. compared three decades in gastric cancer surgery in a Portuguese hospital and found an increase of EGC from 14.5% in the time span from 1980 to 1989 compared to 20.8% in the time span from 2000 to 2009. Data from Italian Research Group of Gastric Cancer showed a decreasing rate of patients with resected gastric cancer from 1991 to 2005 and during the same time span a decreasing rate of pT1 gastric cancer. But the rate of stage I carcinoma was not different in the three five years sections with 37.8%, 35.4% and 37.4%. In Germany, there are three prospective multicenter observational studies: the German Gastric Cancer Study (GGCS ’92) with data from 19 University hospitals in the time span 1986-1989, the quality assurance study of the East German study group for quality assurance and regional development in surgery (EGGCS ’02) including the data from 2007-2009 study. For the study from QCGC 2007-2009, data from 141 hospitals (QCGC 2007-2009) including the data from 2007-2009 was not different in the three five years sections with 37.8%, 35.4% and 37.4%. In current European countries the ASR for males is about 16 per 100000 inhabitants.

THERAPEUTIC OPTIONS FOR EGC

Treatment options for early gastric cancer range from endoscopic mucosal resection (EMR), endoscopic sub-
mucosal dissection (ESD), laparoscopic or open distal gastric resection to gastrectomy with radical lymph node dissection.

EMR has become the standard of care for removal of large flat and sessile neoplastic lesions of the gastrointestinal tract in Japan and Korea. The applications of EMR and ESD are expanding and many Western endoscopists are adopting these techniques. But according to the low frequency of early gastric cancer in Western countries and the high frequency of lymph node metastases in those EGC the standard of care is the gastrectomy.

### ENDOSCOPIC TREATMENT

Endoscopic treatment (ER): EMR as well as ESD of early carcinomas is only meaningful if lymph node metastasis can be excluded. This is not possible by endoscopic ultrasonography or computed tomography because the size of the lymph nodes (LN) is not a reliable parameter for detection of metastatic infiltration. This has been shown for early as well as advanced gastric cancer. Therefore, the indication for endoscopic treatment is an on-going debate between surgeons and gastroenterologists.

EMR: Since endoscopic mucosal resection using the strip biopsy method (two-channel method) was first introduced for endoscopic therapy in 1984, various methods of EMR have been developed, including endoscopic resection with a cap-fitted panendoscope (EMRC). They are widely used in Western countries as well as Japan and small diffuse carcinomas an endoscopic treatment can be considered.

### SURGICAL TREATMENT

The surgical resection of the tumor is the only possibility to cure a patient with early gastric cancer and lymph node metastasis. The age-adjusted survival rates for these patients are comparable with the normal population. The presence of lymph node metastasis is one of the most important prognostic factors in patients with gastric carcinoma. Node-negative patients have a better outcome, nevertheless a subgroup of them experience disease recurrence. Baiocchi et al. analyzed the clinicopathological characteristics of lymph node-negative advanced gastric carcinoma patients submitted to gastrectomy and D2 lymphadenectomy with a retrieved number of lymph nodes (LNM) for early gastric carcinoma.
of nodes greater than 15, after an actual follow-up of almost 5 years, and evaluate outcome indicators. Data of 301 patients with curative gastrectomy staged as N0 between 1992 and 2002 of 7 centers participating to the Italian Research Group for Gastric Cancer were included. Disease-specific and disease-free survival after 3, 5, and 10 years were 90.4%, 86.1%, 75.9%, and 72.1%, 57.3%, 57.3%, respectively. Mortality was 1.7%. The factors associated with a better disease-free survival at univariate analysis were age < 60, T2 tumors, distal location, intestinal histotype, and number of retrieved nodes > 25; depth of infiltration and histotype were the only 2 independent predictors of 5-year recurrence-free survival at multivariate analysis.

Therefore, the German national guidelines for gastric cancer suggests that only mucosal cancer without LNM can be treated endoscopically if a R0-resection is possible[9].

The guidelines do not dictate the indication for a subtotal gastrectomy, however a D2 lymphadenectomy and a resection margin of 5 cm for intestinal type and 8 cm for diffuse type of gastric cancer is provided. As Hosokawa et al[31] show a subtotal gastrectomy to be equal to total gastrectomy concerning the outcome of early remnant gastric cancer patients who underwent endoscopic treatment at first; there is evidence for the efficiency of the limited surgical treatment. But so far, there is a lack of data regarding this approach in early gastric cancer in western countries.

LYMPHADENECTOMY

For many years, clinicians have debated whether an extended lymph-node dissection (D2) for gastric cancer is beneficial. So far, five randomised studies comparing D1 and D2 dissections have been completed. A Cochrane review showed a significantly increased mortality after D2 dissection (RR = 2.23, 95%CI: 1.45-3.45), without a benefit in survival; HR = 0.95, 95%CI: 0.83-1.09[36].

A single-centre randomised trial comparing D1 and D3 dissections was the first to identify a difference (P = 0.041) between overall survival in D1 dissections (53.6%, 95%CI: 44.2-63.0) and D3 dissections (59.5%, 95%CI: 50.3-68.7). No postoperative deaths occurred and morbidity was 12%. Only 13% of patients in this study had pancreatoco-splenectomy compared with 23% in the Dutch gastric cancer trial[39]. Analysis of the group that did not undergo a pancreatoco-splenectomy in the Dutch trial showed a significant survival advantage for those who had a D2 lymph-node. Thus, a D2 dissection might be beneficial if postoperative mortality can be avoided. Strong et al[39] compared pT1 pN0 gastric cancer from United States with those from Korea. They could show that if patients had a D2-lymphadenectomy the prognosis was comparable for both groups of patients. Instead of these results the guidelines for the extension of lymphadenectomy for early cancer is different between Europe and United States. National guidelines from the Netherlands or from Germany recommended a D2-LAD for resectable gastric cancer[34]. The actual version of The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer recommended for patients with resectable locoregional cancer, a gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a limited lymph node dissection for this group of patients[34].

PREDICTION OF LYMPH NODE METASTASES

The key issue for the decision of endoscopic or surgical treatment is the existence of lymph node metastasis. For rational LN dissection it is important to know the incidence of metastasis at each LN station. For this purpose a computer program was developed using data from 4302 primary gastric cancers treated at the National Cancer Center Hospital in Tokyo between 1969 and 1989[40]. The accuracy of this program for European patients was evaluated by several authors[41-43]. The Maruyama computer program showed good predictive ability for LN metastases in most of the 16 LN stations. The predictive values could be improved using a neural network for the prediction of LN metastases[44,45,48].

The probability of lymph node metastasis is a key criterion for defining subgroups of patients for whom these endoscopic methods are appropriate. The main focus of the current discussion is m3 and sm1. Hölscher et al[46] described an algorithm for a group of patients with early cancer in Germany using only variables which are available before therapeutic decision. Using this clinical pathway all carcinomas with lymph node metastasis and 50% of those without LNM were correctly predicted.

A more invasive method is the Sentinel lymph node (SN) biopsy. The technique is based on the concept that the tumor-bearing status of the SN, which is defined as a LN that directly drains a specific cancer, reflects the tumor status of the remaining nodes. In a Japanese multicenter trial the feasibility and accuracy of diagnosis using SN biopsy in T1 gastric cancer was evaluated. The proportion of false negatives was much higher than expected. And the authors conclude that intraoperative histological examination using only one plane is not an appropriate method for clinical application of SN biopsy in gastric cancer surgery[47].

MINIMAL-INVASIVE SURGERY

Since the first report of laparoscopic gastrectomy in 1994 by Kitano et al[41] in Japan, much of our knowledge on the feasibility, safety, and benefits of laparoscopy in the treatment of gastric cancer is derived from studies performed
in the East. Data from the West have emerged at a slower pace. This is largely because the disease incidence is much lower and a greater proportion of patients present with locally advanced tumors that render laparoscopic resection less feasible. In addition, up to 50% of gastrectomies for adenocarcinoma in the US are performed at low volume centers where experience with advanced laparoscopic gastric surgery is limited. As a result, conventional open gastrectomy is still performed much more frequently in the US than laparoscopic resection even for patients with early stage disease. Corcione performed during a time span of 12 years laparoscopic gastrectomy with D2-lymphadenectomy in 11 patients with early gastric cancer. The five year survival rate was 100% (95). In Japan, early stage gastric cancer (T1NO or T2N0) is regarded as the only indication for laparoscopic gastrectomy. Cancer registry data from United States as well as from the Netherlands showed that more than 90% of the patients with stage I gastric cancer were surgically resected (96).

CONCLUSION

Physicians from Western countries had much learned about treatment of gastric cancer from the great experience of their Eastern colleagues. Patients with adequate treated early gastric cancer have the same prognosis as normal population. Therefore the main goal of future research is to reduce the side effects of the therapy and to improve the quality of life after therapy. Actual topic of cancer research is personalized therapy. One example may be the ToGA-trial (Trastuzumab for Gastric Cancer), the first international trial to include patients with human epidermal growth factor 2 (HER-2) positive advanced/metastatic gastric or gastroesophageal junction cancer. For patients with HER-2 positive advanced gastric cancer Trastuzumab, an anti-HER2 monoclonal antibody, survival benefit was shown and becomes the first targeted agent approved in these tumors (97). But only 20% or less of all patients are HER-2 positive. To date, monoclonal antibody therapy is the only immunotherapy approved by the United States Food and Drug Administration for gastrointestinal cancers. Initial trials validating new immunotherapeutic approaches, including vaccination-based and adoptive cell therapy strategies, for gastrointestinal malignancies have demonstrated safety and the induction of antitumor immune responses. Therefore, immunotherapy is at the forefront of neoadjuvant as well as adjuvant therapies for the treatment and eradication of gastric cancer (98,99).

REFERENCES

1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078]
2 Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24 [PMID: 11597040]
3 Sano T, Kataki H, Sasaki M, Maruyama K. The management of early gastric cancer. Surg Oncol 2000; 9: 17-22 [PMID: 11525302]
4 Niininen A, Kokkola A, Ylä-Liedenpohja J, Louhimo J, Mustonen H, Puolakkainen P. Early gastric cancer: clinical characteristics and results of surgery. Dig Surg 2009; 26: 378-383 [PMID: 19923295 DOI: 10.1159/00026765]
5 Saragoni L, Morgagni P, Gardini A, Marfisi C, Vittimberga G, Garcea D, Scapin E. Early gastric cancer: diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. Gastric Cancer 2013; 16: 549-554 [PMID: 23423491 DOI: 10.1007/s10120-013-0233-2]
6 Baambo 2M, Strong VE. Minimally invasive surgery for gastric cancer. J Surg Oncol 2013; 107: 271-276 [PMID: 22903545 DOI: 10.1002/jso.22337]
7 Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc 2012; 76: 763-770 [PMID: 22884100 DOI: 10.1016/j.gie.2012.06.014]
8 Othman MO, Wallace MB. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) in 2011, a Western perspective. Clinics and Research in Hepatology and Gastroenterology 2011; 35: 286-294 [DOI: 10.1016/j.clinre.2011.02.006]
9 Sobin L, Gospodarowicz M, Wittekind C. UICC (2009) TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell, 2010
10 Hölcscher AH, Drebber U, Mönig SP, Schulte C, Vallböhmer D, Bollschweiler E. Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration. Ann Surg 2009; 250: 791-797 [PMID: 19809298 DOI: 10.1097/SLA.0b013e3181d3e34]
11 Folli S, Dente M, Dell’Amore D, Gaudio M, Nanni O, Saragoni L, Vio A. Early gastric cancer: prognostic factors in 223 patients. Br J Surg 1995; 82: 952-956 [PMID: 7648118]
12 Hayes N, Karat D, Scott DJ, Raines SA, Griffin SM. Radical lymphadenectomy in the management of early gastric cancer. Br J Surg 1996; 83: 1421-1423 [PMID: 894462]
13 Bösing N, Verreet PR, Ohmann C, Röher HD. [Early stomach carcinoma—pathologic-anatomic findings and prognosis]. Chirurg 1996; 69: 259-263; discussion 264 [PMID: 9576036]
14 Popiela T, Kulig J. Kolodziejczyk P, Sierzeza M. Long-term results of surgery for early gastric cancer. Br J Surg 2002; 89: 1035-1042 [PMID: 12153632 DOI: 10.1046/j.1365-2168.2002.02156.x]
15 Roviello F, Rossi S, Marrelli D, Pedrazzani C, Corso G, Vindigni C, Morgagni P, Saragoni L, de Manzoni G, Tommazzi A. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 2006; 94: 275-280; discussion 274 [PMID: 16917863 DOI: 10.1002/jso.20566]
16 Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K, Siewert JR. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 1993; 71: 2918-2925 [PMID: 8490819]
17 Noguchi Y, Yoshikawa T, Tsuburaya A, Motohashi H, Karpeh MS, Brennan MF. Is gastric carcinoma different between Japan and the United States? Cancer 2000; 89: 2237-2246 [PMID: 1147594]
18 Faria GR, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, Esheman CR, Rabin BS. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut 2011; 60: 1644-1649 [PMID: 21613644 DOI: 10.1136/gut.2010.206737]
19 Faria GR, Pinto-de-Sousa J, Preto JR, Sousa HS, Barbosa JA, Costa-Maia J. Three decades of clinical-pathological trends in gastric cancer: prospective data from a Portuguese hospital. Int J Surg 2013; 11: 472-476 [PMID: 23602895 DOI: 10.1016/j.ijsu.2013.04.004]
20 Marrelli D, Pedrazzani C, Morgagni P, de Manzoni G, Pacelli F, Coniglio A, Marchet A, Saragoni L, Giacopuzzi S, Roviello F. Changing clinical and pathological features of
Bollschweiler E et al. Treatment of early gastric cancer

gastric cancer over time. Br J Surg 2011; 98: 1273-1283 [PMID: 21560122 DOI: 10.1002/bjs.7528]

21 Roder JD, Böttcher K, Siewert JR, Busch R, Hermannek P, Meyer HJ. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72: 2089-2097 [PMID: 8374867]

22 Meyer L, Steinert R, Nowak L, Gellert L, Ludwig K, Saeger D, Gastinger I, Lippert H. [Prospective multicenter trial of gastric cancer surgery--a contribution to clinical research on quality control]. Zentralbl Chir 2005; 130: 97-105 [PMID: 15849650 DOI: 10.1055/s-2005-836491]

23 Ridwelski K, Gastinger I, Ptok H, Meyer F, Dralle H, Lippert H. [Surgical treatment of gastric carcinoma. German multicenter observational studies]. Chirurg 2013; 84: 46-52 [PMID: 23239211 DOI: 10.1007/s00464-012-2394-7]

24 Maehara Y, Orita H, Okuyama T, Moriguichi S, Tsujitani S, Korenaga D, Sugimachi K. Predictors of lymph node metastasis in early gastric cancer. Br J Surg 1992; 79: 245-247 [PMID: 1555092]

25 Mönig SP, Schuchmann Z, Schindler W, Schmid RM, Schmidberger H, Schmiegel WH, Scholl MJ, Schuch H, Schuhmacher C, Schütte K, Schwend W, Selgrad M, Senderl A, Seraphin J, Seufferlein T, Stahl M, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Trenk V, Vanhoef K, Vieth M, Vogelsang H, Wagner D, Wedding U, Weismann A, Wilke H, Wittekind C, AWMF, AWMF. [German S3 guideline “Diagnosis and treatment of esophago-gastric cancer”]. Z Gastroenterol 2011; 49: 461-531 [PMID: 21476183 DOI: 10.1007/s00313-012-2720-1]

26 Bollschweiler E, Metzger R, Drebber U, Leers JM, Holscher AH. Differences of pT1 Esophageal and Gastric Adenocarcinoma Comparing Upper, Middle and Lower Third Muscular or Submucosal Infiltration. Gastroenterology 2011; 140: S668-S668

27 Baiochi GL, Tiberio GA, Minicozzi AM, Morgaini P, Marzilli D, Bruno L, Rosa F, Marchet A, Coniglio A, Saragoni L, Veltzi M, Pacelli F, Roviello F, Nitti D, Giuliani SM, De Manzoni G. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg 2010; 252: 70-72 [PMID: 20562605 DOI: 10.1097/ SLA.0b013e3181e4585e]

28 Hosokawa Y, Konishi M, Sahara Y, Kinoshita T, Takahashi S, Gotohda N, Kato Y, Kinoshita T. Limited subtotal gastrectomy for early remnant gastric cancer. Gastric Cancer 2014; 17: 352-336 [PMID: 23832238 DOI: 10.1007/s10120-013-0280-8]

29 McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004; 1: CD001964

30 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477-490 [PMID: 19625077 DOI: 10.1016/S0140-6736(09)60617-6]

31 Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah MA, Cott DG, Brennan MF. Comparison of disease-specific survival in the United States and Korea after resection for early-stage node-negative gastric carcinoma. J Surg Oncol 2013; 107: 634-640 [PMID: 23192297 DOI: 10.1002/jso.23288]

32 Ajani JA, Benetrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, Fakh FGC, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofsletter W, Ilson DH, Kesswani RN, Kleinberg LR, Korn WM, Lockheed GM, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMili- lian NR, Sundar H. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013; 11: 531-546 [PMID: 23667204]

33 Kampschoer GH, Marayuma K, van de Velde CJ, Sasako M, Kinoshita T, Okabayashi K. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989; 76: 905-908 [PMID: 2804584]

34 Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Marayuma K, Siewert JR. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Marayuma computer program. Br J Surg 1992; 79: 156-160 [PMID: 1555065]

35 Droste K, Bollschweiler E, Waschulaik T, Schütz T, Engelbrecht R, Marayuma K, Siewert JR. Prediction of lymph node metastasis in gastric cancer patients with neural networks. Cancer Lett 1996; 109: 141-148 [PMID: 9020913]

36 Bollschweiler EH, Mönig SP, Hensler K, Baldus SE, Marayuma K, Holscher AH. Artificial neural network for prediction of lymph node metastasis in gastric cancer: a phase II diagnostic study. Ann Surg Oncol 2004; 11: 506-511 [PMID: 15123460 DOI: 10.1245/ASO.2004.04.019]
46 Guadagni S, de Manzoni G, Catarci M, Valentì M, Amicucci G, De Bernardinis G, Cordiano C, Carboni M, Maruyama K. Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg 2000; 24: 1550-1558 [PMID: 11193722]

47 Miyashiro I, Hiratsuka M, Sasako M, Sano T, Mizusawa J, Nakamura K, Hashimoto A, Tsuburaya A, Fukushima N. High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302. Gastric Cancer 2014; 17: 316-323 [PMID: 23933782 DOI: 10.1007/s10120-013-0285-3]

48 Kitano S, Tomikawa M, Iso Y, Hashizume M, Moriyama M, Sugimachi K. Laparoscopy-assisted devascularization of the lower esophagus and upper stomach in the management of gastric varices. Endoscopy 1994; 26: 470-473 [PMID: 7956957 DOI: 10.1055/s-2007-1009006]

49 Corcione F, Pirozzi F, Cuccurullo D, Angelini P, Cimmino V, Settembre A. Laparoscopic total gastrectomy in gastric cancer: our experience in 92 cases. Minim Invasive Ther Allied Technol 2013; 22: 271-278 [PMID: 23154441 DOI: 10.3109/13643909.2012.743919]

50 Dassen AE, Dikken JL, van de Velde CJ, Wouters MW, Bosscha K, Lemmens VE. Changes in treatment patterns and their influence on long-term survival in patients with stages I-III gastric cancer in The Netherlands. Int J Cancer 2013; 133: 1859-1866 [PMID: 23564267 DOI: 10.1002/ijc.28192]

51 Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Leidle M, Rutschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/s0140-6736(10)61121-x]

52 Toomey PG, Vohra NA, Ghansah T, Sarmaik AA, Pilon-Thomas SA. Immunotherapy for gastrointestinal malignancies. Cancer Control 2013; 20: 32-42 [PMID: 23302905]

53 Li W, Zhao H, Qian W, Li H, Zhang L, Ye Z, Zhang G, Xia M, Li J, Gao J, Li B, Kou G, Dai J, Wang H, Guo Y. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 2012; 33: 5349-5362 [PMID: 22542611 DOI: 10.1016/j.biomaterials.2012.04.016]
